Your browser doesn't support javascript.
loading
Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
Lee, Sung Won; Huang, Daniel Q; Bettencourt, Ricki; Ajmera, Veeral; Tincopa, Monica; Noureddin, Nabil; Amangurbanova, Maral; Siddiqi, Harris; Madamba, Egbert; Majzoub, Abdul M; Nayfeh, Tarek; Tamaki, Nobuharu; Izumi, Namiki; Nakajima, Atsushi; Yoneda, Masato; Idilman, Ramzan; Gumussoy, Mesut; Oz, Digdem Kuru; Erden, Ayse; Loomba, Rohit.
Afiliação
  • Lee SW; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Huang DQ; Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Bettencourt R; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Ajmera V; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Tincopa M; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Noureddin N; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Amangurbanova M; Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
  • Siddiqi H; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Madamba E; Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
  • Majzoub AM; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Nayfeh T; Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
  • Tamaki N; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Izumi N; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Nakajima A; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Yoneda M; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Idilman R; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Gumussoy M; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Oz DK; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Erden A; Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.
  • Loomba R; Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.
Aliment Pharmacol Ther ; 59(1): 80-88, 2024 01.
Article em En | MEDLINE | ID: mdl-37968251
ABSTRACT

BACKGROUND:

Progression to cirrhosis in non-alcoholic steatohepatitis (NASH) is associated with a decrease in liver fat. However, the prognostic significance of liver fat content in NASH-related significant fibrosis and cirrhosis is unclear.

AIM:

To investigate the risk of decompensation, hepatocellular carcinoma (HCC) and mortality stratified by liver fat content in NASH-related significant fibrosis and cirrhosis.

METHODS:

In this meta-analysis of individual participant data, 456 patients with both magnetic resonance elastography (MRE) and MRI-derived protein density fat fraction (MRI-PDFF) were enrolled, and 296 patients with longitudinal follow-up were analysed. MRE combined with fibrosis-4 (MEFIB-index), and MRI-PDFF were used to measure liver fibrosis and fat, respectively. MEFIB-negative, MEFIB-positive+ MRI-PDFF ≥5% and MEFIB-positive+ MRI-PDFF <5% were defined as no significant liver fibrosis, NASH with significant fibrosis and higher liver fat content, and NASH with significant fibrosis and low liver fat content groups, respectively. The primary outcome was hepatic decompensation, HCC and death.

RESULTS:

The rates of decompensation, HCC and mortality were highest in the NASH with significant fibrosis and low liver fat group (33%, 17% and 17%, respectively), followed by the NASH with significant fibrosis and higher liver fat group (18%, 13% and 13% respectively), and lowest in the no significant fibrosis (MEFIB-negative) group (0%, 1% and 2% respectively). In multivariable-adjusted analysis, low liver fat content was strongly associated (HR = 42.2 [95% CI 7.5-235.5, p < 0.0001]) with HCC, decompensation and death. Sensitivity analyses for patients with cirrhosis (MRE ≥5 kPa) determined consistent findings.

CONCLUSIONS:

Low liver fat content in patients with burnt-out NASH-related significant fibrosis and cirrhosis is associated with an increase in hepatic decompensation, HCC and mortality.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Aliment Pharmacol Ther Assunto da revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Aliment Pharmacol Ther Assunto da revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
...